Article
JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Genes & development - 1 Jun 2018
Kim Sang-Kyu, Knight Deborah A, Jones Lisa R, Vervoort Stephin, Ng Ashley P, Seymour John F, Bradner James E, Waibel Michaela, Kats Lev, Johnstone Ricky W
Abstract excerpt
Activating JAK2 point mutations are implicated in the pathogenesis of myeloid and lymphoid malignancies, including high-risk B-cell acute lymphoblastic leukemia (B-ALL). In preclinical studies, treatment of JAK2 mutant leukemias with type I JAK2 inhibitors (e.g., Food and Drug Administration [FDA]-approved ruxolitinib) provided limited single-agent responses, possibly due to paradoxical JAK2Y1007/1008...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.